A. J. Montero - Curriculum Vitae - 2
Updated 1/06/09
CURRICULUM VITAE
I. PERSONAL
Name Alberto José Montero
Date of Birth October 11, 1971
Current position Assistant Professor of Medicine
Current work address University of Miami
Sylvester Comprehensive Cancer Center
1550 NW 10th Avenue
Fox Building #305
Miami, FL 33136
Languages Spanish and English
Citizenship U.S.
II. EDUCATION AND TRAINING
August, 1990 – December, 1995 Bachelor of Arts
Major, Philosophy and Psychology
University of Texas
Austin, TX
May, 1995 – May, 1999 Doctor of Medicine
University of Texas Medical Branch
Galveston, TX
June, 1999 – June, 2002 Internal Medicine Residency
Physician Scientist Pathway
University of Texas Health Science Center
Houston, TX
June, 2002 – June, 2005 Hematology-Oncology Fellowship
University of Texas M. D. Anderson Cancer Center
Houston, TX
Present Position
July, 2008-Present Assistant Professor of Medicine
Division of Hematology-Oncology
University of Miami, Miller School of Medicine
Specialty/Board Certification:
2002 Internal Medicine
2005 Hematology/Oncology
Licensure:
2002-2005 Texas
2005-2009 South Carolina
May, 2008-Present Florida
III. ACADEMIC APPOINTMENTS
July, 2005 – July, 2008 Assistant Professor of Medicine Division of Hematology-Oncology
Medical University of South Carolina
Charleston, SC
Other Appointments
January, 2006-July, 2008 Associate Fellowship Director for Hematology/Oncology
IV. PUBLICATIONS
Peer Reviewed Journal Articles:
Crump WJ, Tessen RJ, and Montero AJ. “The department without walls. Acceptability, cost, and utilization of interactive video technology.” Archives of Family Medicine. 6(3): 273-8, May-June 1997.
Montero AJ, Díaz-Montero CM, Malpica A, and Kavanagh JK. Langerhans cell histiocytosis of the female genital tract: a literature review. International Journal of Gynecologic Cancer 13: 1-8, 2003.
Deng Wu-Guo, Zhu Ying, Montero A, and Wu KK. Quantitative Analysis of Binding of Transcription Factor Complex to Biotinylated DNA Probe By a Streptavadin-Agarose Pulldown Assay. Analytical Biochemistry. 2003 Dec 1;323(1):12-8.
Montero AJ, Fossella F, Valero V, and Hortobagyi G. Docetaxel in Solid Tumors: A Systematic Review of the Clinical Data. Lancet Oncology. 2005 Apr;6(4):229-39.
Montero AJ, Rouzier R, Lluch A, Buzdar A, et al. Long-Term Survival Benefit of Anthracycline- Based Adjuvant Chemotherapy in Breast Cancer Patients with Ten or More Metastatic Axillary Lymph Nodes: a Multi-Institutional Retrospective Study. Cancer. 2005 Jul 15;104(2):229-35.
Montero AJ, Esparza-Guerra L, Murray J, Rosales M, et al. Phase I Study of Dose-Dense Docetaxel and Doxorubicin Every 14 Days with or without GM-CSF in Patients Metastatic Breast Cancer. Drugs R D. 2005;6(5):299-305.
Montero AJ, McCarthy JJ, Chen G, Rice L. Acute Respiratory Distress Syndrome After Rituximab Infusion. Int J Hematol. 2005 Nov;82(4):324-6.
Hayslip J, Montero A. Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Mol Cancer. 2006 Oct 6;5:44.
Montero AJ, Estrov Z, Freireich EJ, Khouri IF, Koller CA, and Kurzrock R. Phase II Study of Low-Dose Interleukin-11 in Patients with Myelodysplastic Syndrome. Leuk Lymphoma. 2006 Oct;47(10):2049-54.
Montero AJ, Diaz-Montero CM, Mao L,Youssef EM, Estecio M, Shen L, and Issa JP. Epigenetic Inactivation of EGFR by CpG Island Hypermethylation in Cancer. Cancer Biol Ther. 2006 Nov;5(11):1494-501. Epub 2006 Nov 19.
Skorupa A, Beldner M, Kraft A, Montero AJ. Fatal Rhabdomyolysis as a complication of Et-743 (Yondelis) Chemotherapy for Sarcoma: Case Report and Literature Review. Cancer Biol Ther. 2007 Apr 24;6(7) [Epub ahead of print].
Deng WG, Montero AJ, Wu, KK. Interferon-γ suppresses cyclooxygenase-2 promoter activity by inhibiting C-Jun and C/EBPβ binding. Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1752-9. Epub 2007 Jun 7.
Diaz-Montero CM, El Naggar S, El Naggar R, Al Khami A, Montero AJ, Cole DJ, Salem ML. Priming of naive cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity Cancer Immunol Immunother. 2008 Apr;57(4):563-72. Epub 2007 Aug 28.
Beldner MA, Green MR, Meyer M, Shannon S, Kraft AS, Sherman C, Montero AJ. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer. 2007 Dec 20;7(1):231.
Hayslip J, Chaudhary U, Green MR, Meyer M, Dunder S, Sherman S, Salzer S, Kraft A, Montero AJ. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 3;7(1):221.
Gudena V, Verma N, Post G, Kizziah M, Fenning R, Montero AJ. Metastatic Chest Wall Malignant Peripheral Nerve Sheath Tumor Responding to Sorafenib: Case Report and Literature Review. Cancer Biol Ther. 2008 Mar 19;7(6) [Epub ahead of print]
Marcela Diaz-Montero C, Salem ML, Garrett-Mayer E, Cole DJ, Montero AJ. Increased Levels of Circulating Myeloid-Derived Suppressor Cells in Solid Tumor Patients Correlate With Advanced Clinical Cancer Stage, Increased Tumor Burden, and Cyclophosphamide Containing
Chemotherapy. Cancer Immunol Immunother. 2008 Apr 30. [Epub ahead of print]
Jiang Y, Kimchi ET, Montero AJ, Staveley-O'Carroll KF, Ajani JA. Upper gastrointestinal tumors: current status and future perspectives. Expert Rev Anticancer Ther. 2008 Jun;8(6):975-91.
Salem ML, Diaz-Montero C, Alkhami, A, Montero AJ, Cole DJ Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination anti-tumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol. (Manuscript Accepted).
Invited Articles:
Montero AJ, Valero Vicente. Treatment of a Patient with Locally Advanced Breast Cancer Treated with Epirubicin-Ccontaining Primary Chemotherapy. Case Studies in Breast Cancer. June 2003.
Montero A, Hortobagyi G. The Evolving Role of Taxanes in the Management of Early Stage And Locally Advanced Breast Cancer. Oncology Exchange. 2004 April: Vol 3 (Suppl 1): 5s-7s.
Zhu Y, Montero AJ, Cornett WR. Genomics in breast cancer; what the surgeon must know. Contemporary Surgery. 2007 May: Vol 63, Issue 5: 299-304.
Jiang Y, Montero AJ, and Staveley-O’Carroll KF. Adjuvant and Preoperative Therapy for Localized Gastric Cancer. Gastrointestinal Cancer Research: Vol 1, Issue 4.
Milling DL, Montero AJ, Jiang Y, Gastrointestinal Stromal Tumors: Review of Molecular Biology and Clinical Implications. Gastrointestinal Cancer Research (Manuscript Accepted).
Book Chapters:
Montero AJ, Varadhachary G, and Abbruzzese, JL. Unknown Primary Cancer: Diagnosis and Management. Medical Oncology: A Comprehensive Review. 3rd Edition.
Submitted Manuscripts
Montero AJ, Diaz-Montero CM, Liu, J, McIntyre BW, Logothetis C, Tannir N. Decreases in IL-6 and IL-8 in Serum of Patients with Metastatic Renal Cell Carcinoma Treated with Interferon Alpha-2b are Strong Independent Predictors of Clinical Benefit.
Seminar Invitations
Breast Cancer Update: Looking Back At 2005. Department of Internal Medicine Grand Rounds, January 2006 Medical University of South Carolina
Breast Cancer Update 2007. South Carolina Medical Association Annual Meeting. May 5, 2007
Medical Issues in Cancer Patients: The Important Role of Primary Care Physicians. South Carolina Medical Association Annual Meeting. May 5, 2007
Presentations At National Meetings
Montero AJ, Shen L, Valero V, and Issa JP. CHFR methylation as a marker of taxane sensitivity in breast cancer. Poster presentation. American Society of Clinical Oncology Annual Meeting. New Orleans, LA. June 4-8, 2004.
Montero AJ, Rouzier R, Lluch-Hernandez A, Kau SW, et al. Long-term survival benefit of anthracycline-containing adjuvant chemotherapy in breast cancer patients with ten or more positive lymph nodes: a multi-institutional retrospective study. Poster presentation. 27th Annual San Antonio Breast Cancer Symposium. December 8-11, 2004.
Montero AJ, Diaz-Montero CM, Mao L, Youssef EM, et al. Epigenetic Inactivation of EGFR-1 by Aberrant Promoter Methylation: Implications for Combining Hypomethylating Drugs and EGFR Inhibitors. Poster Presentation. American Association of Cancer Research meeting Anaheim, CA 2005.
Montero AJ, Diaz-Montero CM, Wang X, McIntyre BW, Tannir N. Predictive Utility of Serum Cytokine Levels in Patients with Metastatic Renal Cell Carcinoma (MRCC) Treated with Interferon Alfa (IFNa). Poster presentation. American Society of Clinical Oncology Annual Meeting. Atlanta, GA 2006.
Beldner MA, Sherman CA, Meyer M, Green MR, Shannon S, Montero AJ, Kraft AS. A Phase I Study of Weekly Topotecan and Vinorelbine in Recurrent Lung Cancer. Abstract. American Society of Clinical Oncology Annual Meeting. Atlanta, GA 2006.
Dunder S, Chaudhary U, Green M, Meyer M, Brescia F, Kraft A, Salzer S, Montero AJ. A Phase I trial of bortezomib and celecoxib in patients with advanced solid tumors. Abstract. American Society of Clinical Oncology Annual Meeting. Atlanta, GA 2006.
N. K. Ibrahim, G. Nguyen, D. Suki, B. Hennessy, A. Montero, J. E. Sarriera, F. Symmans, V. Valero, R. Sawaya, K. Aldape. Clinicopathological correlation (CC) and outcome of breast cancer patients (pts) with resected brain metastasis (BM). Poster Presentation. American Society of Clinical Oncology Annual Meeting. Atlanta, GA 2006.
M. Mitas, A. Graham, A. Khoors, Y. Chen, D. Lewin, P. Davoodi, K. Mikhitarian, A. Montero, D. Cole, M. Wallace. The Ets transcription factor Esx regulates expression of metastasis-associated genes in non-small cell lung cancer (NSCLC). Poster Presentation. American Society of Clinical Oncology Annual Meeting. Atlanta, GA 2006.
A AlKhami, AJ Montero , M Salem, K Vissage, DJ Cole, Marcela Diaz-Montero. Circulating Levels of CD4+ CD25+ T cells Correlate with Clinical Cancer Stage And Inversely Correlate with CD8+ T cells. Poster Presentation. American Association of Immunologists Annual Meeting. Miami, FL 2007.
AJ Montero , M Salem, K Vissage, A AlKhami, DJ Cole, Marcela Diaz-Montero. Circulating Immature Myeloid Cells (ImC) Levels Correlate with Clinical Cancer Stage and Cyclophosphamide (CTX) Treatment. Poster Presentation. American Association of Immunologists Annual Meeting. Miami, FL 2007.
J Brashears, A J Brisendine, U B Chaudhary, N F Esnaola, A J Montero, DT Marshall. Preliminary Results of a Phase II Study of Induction Gemcitabine/Oxaliplatin (GEMOX) and Cetuximab Followed by Surgery or Concurrent Intensity Modulated Radiation Therapy (IMRT) and Capecitabine for Locally Advanced Pancreatic Cancer. Poster Presentation. Radiological Society North America Annual Meeting. Chicago, IL 2007.
U. B. Chaudhary, V. Gudena, D. L. Milling, P. O'Brien, A. J. Montero, J. Brashears, D. Marshall, B. Hoffman, E. Garrett-Mayer, N. Esnaola. Preliminary results of a Phase II neoadjuvant trial with gemcitabine/oxaliplatin and cetuximab followed by surgery or concurrent intensity modulated radiation therapy (IMRT) with capecitabine for patients with borderline resectable and unresectable nonmetastatic pancreatic cancer. Poster Presentation. American Society of Clinical Oncology. Gastrointestinal Cancers Symposium. Orlando, FL 2008.
Montero AJ, Dewaay DJ, Salem M, Cole DJ, Diaz-Montero CM. Circulating immature myeloid cells in breast cancer patients correlate with clinical cancer stage and cyclophosphamide treatment: implications for cancer immunotherapy. Poster Discussion. San Antonio Breast Cancer Symposium. San Antonio, TX 2007.
V. PROFESSIONAL
Extramural and Intramural Grants
2008 Urbieta Colon Cancer Foundation Grant ($48,000)
2006-2007 Research Centers for Minority Aging Research (RCMAR) Scholar ($20,000)
2005-2006 American cancer Society Institutional Research Grant ($19,500)
2005-2006 Chain Reaction for a Cure Foundation ($20,000)
2004-2006 NIH Clinical Research Loan Repayment Program Grant ($55,000)
Current Clinical Protocols as Principal Investigator
Investigator Initiated Studies
Phase II Study of Neoadjuvant Treatment with NOV-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients with Stages IIB-IIIC Breast Cancer (CTO#101072/Novelos; 1/07 $205,325 direct/total; IND 76,582).
Myeloid Suppressor Cells in Breast Cancer (CTO#100953/Chain reaction for a Cure; $20,000 direct/total).
Phase I/II Study of BZL-101 and Weekly Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma or Locally Unresectable or Metastatic Biliary Tract Cancers (Pending IND approval/Bionovo).
Peripheral Blood Molecular Staging of Breast Cancer: A Prospective Cohort Study Designed to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Peripheral Blood of Stage IV Breast Cancer Patients (CTO#101039/Sponsor: WI Gillanders Washington University)
Industry Sponsored Studies
A Phase I Study to Evaluate the Safety/Tolerability and Immunogenecity of V-930 in Patients with Cancers Expressing CEA and/or HER-2 (CTO#100973/Merck).
Phase I/II, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB007839 Following Multiple Oral Doses in Patients with Solid Tumors (CTO#100872/Incyte Corporation).
An Open-Label Study of Capecitabine and Docetaxel as Neoadjuvant Treatment for Patients with Recently Diagnosed HER2-neu Negative Breast Cancer Plus Trastuzumab for HER2-neu Positive Breast Cancer (CTO #100921/Roche).
A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel versus Trastuzumab and Paclitaxel for First Line Therapy of Metastatic Breast Cancer (CTO#100958/Sopherion).
A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V930/V932 in Patients with Cancers Expressing HER-2 and/or CEA (CTO#10184/Merck)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study in Patients with Advanced Carcinoid Tumor Receiving Sandostatin LAR and RAD001 10mg/d or Sandostatin LAR and Placebo (CTO#101071/Novartis)
A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZLl0l for Metastatic Breast Cancer (CTO# 101105/Bionovo).
A Randomized Phase 2 Study of the Ant-Angiogenesis Agent AG013736 in Combination with Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer Preceded by a Phase 1 Portion (CTO#100992/Pfizer)
Cooperative Group Trials
A Randomized Phase III Trial of Exemestane versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer” (CTO# 101014/MA. 27).
Phase III Randomized Trial of Anastrozole Vs Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer (CTO#100991/SWOG S0226).
A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (CTO# 101012/ IBCSG-25-02).
A Double-blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma (CTO# 101082/ECOG 2603).
Completed Investigator Initiated Studies
Circulating Tumor Cells in Metastatic Hormone Receptor Positive Breast Cancer (CTO# 100926/ACS).
Phase I Trial of Bortezomib (VELCADETM) and Celecoxib in Patients with Advanced Solid Tumors (CTO# 100825/ Millennium).
Phase I Study of Topotecan in Combination with Vinorelbine in Recurrent Lung Cancer (CTO #104864/GSK).
Editorial Responsibilities
Reviewer
2005-Present The American Journal of Medical Sciences
2005-Present Drugs RD
2006-Present Southern Medical Journal
Professional/scientific societies:
2002-Present American Society of Clinical Oncology
2003-Present American Association of Cancer Research
2006-Present Member of Breast Cancer Committee Southwest Oncology Group (SWOG)
Honors and Awards:
2005 American Cancer Society Institutional Research Grant Award